These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. Frasci G; Tortoriello A; Facchini G; Conforti S; Persico G; Mastrantonio P; Cardone A; Iaffaioli RV Eur J Cancer; 1994; 30A(7):946-50. PubMed ID: 7946589 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH; Valea F; Walton LA; Soper J; Clarke-Pearson D; Fowler WC Gynecol Oncol; 1995 Nov; 59(2):267-72. PubMed ID: 7590485 [TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. Ferrari E; Maffeo DA; Graziano R; Gallo MS; Pignata S; De Rosa L; Montella M; Pergola M Eur J Gynaecol Oncol; 1994; 15(6):437-42. PubMed ID: 7875158 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of ovarian carcinoma with intraperitoneal administration of interferon alpha 2b]. Ambrosio D; Piscopo L; Lauro C; Rotondi M; Gallo E; Balbi F Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):67-71. PubMed ID: 11526725 [TBL] [Abstract][Full Text] [Related]
7. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. Mäenpää J; Kivinen S; Räisänen I; Sipilä P; Väyrynen M; Gröhn P Ann Chir Gynaecol Suppl; 1994; 208():25-7. PubMed ID: 8092765 [TBL] [Abstract][Full Text] [Related]
9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502 [TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Bezwoda WR; Seymour L; Dansey R Cancer; 1989 Sep; 64(5):1029-33. PubMed ID: 2758381 [TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418 [TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal interferon in the management of malignant ascites. Stuart GC; Nation JG; Snider DD; Thunberg P Cancer; 1993 Mar; 71(6):2027-30. PubMed ID: 7680276 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Sartori S; Nielsen I; Tassinari D; Trevisani L; Abbasciano V; Malacarne P Oncology; 2001; 61(3):192-6. PubMed ID: 11574774 [TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550 [TBL] [Abstract][Full Text] [Related]
15. [Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease]. Cherchi PL; Dessole S; Esposito F; Ambrosini G; El Qandil FZ; Ambrosini A J Gynecol Obstet Biol Reprod (Paris); 1996; 25(1):101-2. PubMed ID: 8901311 [No Abstract] [Full Text] [Related]
16. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi PG; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte PF Gynecol Oncol; 1997 Jun; 65(3):499-505. PubMed ID: 9190982 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428 [TBL] [Abstract][Full Text] [Related]
18. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389 [TBL] [Abstract][Full Text] [Related]
19. The treatment of microscopic residual ovarian cancer with intraperitoneal interferon: a clinical and flow cytometric study. Whelan JS; van Dam PA; Shepherd JH; Slevin ML Br J Obstet Gynaecol; 1992 Jul; 99(7):615-7. PubMed ID: 1525107 [No Abstract] [Full Text] [Related]
20. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study. Repetto L; Chiara S; Guido T; Bruzzone M; Oliva C; Ragni N; Conte PF; Rosso R Anticancer Res; 1991; 11(4):1641-3. PubMed ID: 1746921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]